Latest / Stock Movers / ABB Soars, Legrand Rises, Novartis Down
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios podcasts, radio news, The.
- 0:08Speaker 2: Stock Movers podcast, your roundup of companies making moves in
- 0:13Speaker 2: the stock market, harnessing the power of Bloomberg Data.
- 0:17Speaker 3: I'm Caroline Hepget alongside Tom McKenzie. We're joined now by
- 0:21Speaker 3: Bloomberg's Breaking News editor, Chlone Malay.
- 0:24Speaker 4: Good morning, Chloe.
- 0:25Speaker 3: So ABB shares have sawed this morning. I'm still of
- 0:30Speaker 3: tried to get used to their new phrase engineered to
- 0:34Speaker 3: outrun that came in last year.
- 0:36Speaker 4: Are they outrunning? Why?
- 0:38Speaker 2: Oh yeah?
- 0:39Speaker 1: So quite good news, very good news actually from ABB
- 0:42Speaker 1: this morning. It reported very strong order growth, actually record
- 0:45Speaker 1: auder intake in the second quarter. So ABB makes power
- 0:50Speaker 1: and automation tools for factories, and it said that demand
- 0:53Speaker 1: was very strong, very solid, especially in the US. So
- 0:56Speaker 1: if we look at the electrification unit in particular, that
- 0:59Speaker 1: was particularly robust, and that unit supplies power companies, and
- 1:04Speaker 1: that is solid because of the fact that the AI
- 1:07Speaker 1: boom is driving investment in data centers, which is in
- 1:10Speaker 1: turn driving investment in electrical grids, which is then benefiting ABB.
- 1:15Speaker 1: Investors reacted very positively to the news and going forward,
- 1:18Speaker 1: the CEO was very optimistic. He said that the company
- 1:21Speaker 1: was on the path towards a record year, and obviously
- 1:24Speaker 1: he did flag that, you know, that was despite some
- 1:27Speaker 1: uncertainties of course in the global environment.
- 1:29Speaker 4: That's a caveat that.
- 1:30Speaker 1: We're likely going to see a bit more for the
- 1:33Speaker 1: rest of this ending seasons from the CEOs so.
- 1:37Speaker 4: For ABEB to Francis Legment and there's some games coming through.
- 1:41Speaker 4: Here's what's sappening with this business.
- 1:43Speaker 1: Yeah, well, since we're talking about AI, let's talk about
- 1:45Speaker 1: kind of another aspect of it, which is where Lagran
- 1:47Speaker 1: fits into this. So companies that kind of provide the
- 1:50Speaker 1: cooling equipment, the server ACKs, the electrical equipment that I
- 1:54Speaker 1: used in data centers. Those companies are not always kind
- 1:57Speaker 1: of household names, but they are crucial for the broader
- 2:00Speaker 1: air industry. And one of them is Lacarmo French company,
- 2:03Speaker 1: and this morning it raised its four year target for
- 2:06Speaker 1: sales growth and that's because of that strong demand from
- 2:09Speaker 1: data centers. That also pushed the shares up for one
- 2:13Speaker 1: of its key piers.
- 2:15Speaker 4: Which is Schneider Electric.
- 2:17Speaker 1: They have both been talking about the opportunity that comes
- 2:20Speaker 1: with the AI rush and that's really helped them kind
- 2:23Speaker 1: of offset the weaker demand and their kind of other
- 2:26Speaker 1: key markets like the European residential market, for example, or
- 2:29Speaker 1: the US office market.
- 2:32Speaker 4: Okay, so that's on Lacart and ABB.
- 2:35Speaker 3: Nevatis has with released some sales figures, but they seem
- 2:40Speaker 3: quite disappointing.
- 2:41Speaker 1: Yeah, so it's quite an interesting story from Nevatas this morning,
- 2:44Speaker 1: with kind of both positive and more negative news.
- 2:46Speaker 4: Let's start with the positives. It raised its guidance for
- 2:49Speaker 4: the year.
- 2:50Speaker 1: That's due to kind of strong sales of its cancer
- 2:52Speaker 1: medicines in particular, and it also announced a new buyback
- 2:55Speaker 1: of as much as ten billion dollars to be completed
- 2:58Speaker 1: by twenty twenty seven.
- 2:59Speaker 4: But on the other hand, on the more kind of.
- 3:00Speaker 1: Negative side, the sales for its siasis drug called Coscentics
- 3:04Speaker 1: really disappointed, and generally some of its key drugs are
- 3:08Speaker 1: facing increasing competition from cheaper generic drugs that are coming
- 3:12Speaker 1: through this year, including one of its other key medicine medicines,
- 3:17Speaker 1: which is a hot medicine called Entresto. In addition to that,
- 3:20Speaker 1: the chief financial officer is also leaving after twenty two
- 3:24Speaker 1: years and almost ten years, oh no more than ten
- 3:26Speaker 1: years as the finance chief. Just to kind of give
- 3:29Speaker 1: a sense of how this person is thought about in
- 3:33Speaker 1: the industry. One analyst said that he was widely considered
- 3:35Speaker 1: to be the best CFO in the industry, so obviously
- 3:38Speaker 1: not great for nov artists to be losing this CFO.
- 3:44Speaker 1: Over All, the negative news did offset the positives, and
- 3:47Speaker 1: the shares have been a little bit pressured this morning. Now,
- 3:50Speaker 1: going forward, the key thing for novartists is going to
- 3:54Speaker 1: see We're going to see if the bet that it
- 3:56Speaker 1: has made on new medicines is really going to pay
- 3:58Speaker 1: off going forward.
- 4:00Speaker 2: The Stockmovers podcast from Bloomberg Radio. Check back with us
- 4:05Speaker 2: throughout the day for the latest roundup of companies making
- 4:08Speaker 2: news on Wall Street and for the latest market moving headlines.
- 4:11Speaker 2: Listen to Bloomberg Radio Live, catch us on YouTube, Bloomberg
- 4:15Speaker 2: dot com, and on Applecarplay and Android Auto with the
- 4:18Speaker 2: Bloomberg Business app.